Cambridge Healthtech Institute’s 3rd Annual

Emerging Immuno-Oncology Targets

Novel Targets and Pathways for Cancer Immunotherapy and Combinations

August 8-9, 2019



While cancer immunotherapy has made a giant leap in the past five years, the majority of therapies at advanced stages of development are clustered in a similar target space. The increased investment in immuno-oncology has created an urgent opportunity to discover and populate new target spaces that either present new classes of immunotherapies or can be used in combination with existing products. Cambridge Healthtech Institute’s Third Annual Emerging Immuno-Oncology Targets conference will cover the emerging target space, including immunomodulatory inhibitor and agonist targets, stromal and immune cell targets, and strategies for rational combination immunotherapy. Case studies of preclinical and translational approaches to the discovery and validation of new immuno-oncology targets and combinations will be presented. 

EMERGING TARGETS FOR COMBINATION IMMUNOTHERAPY

Understanding Immune Checkpoint TIM-3 Biology and Anti-TIM-3 Antibody for Cancer Immunotherapy
Xiaomo Jiang, PhD, Investigator, Immuno-Oncology, Novartis Institutes for BioMedical Research

Combining OX40 Agonists with TGFb and PD-1 Inhibitors
Andrew Weinberg, PhD, Chief, Laboratory of Basic Immunology, Providence Health & Services

TARGETING INNATE IMMUNITY

Novel, High-Potency STING Agonists Regress Immunotherapy-Resistant Cancers
Michael A. Curran, PhD, Associate Professor, Immunology, Scientific Director, ORBIT Platform, The University of Texas MD Anderson Cancer Center

Coordinate Targeting of Innate and Adaptive Immunity for Cancer Immunotherapy
Jon Wigginton, MD, Senior Vice President, Clinical Development & CMO, MacroGenics

CYTOKINES: TARGETS AND THERAPEUTICS

Development of TNF Superfamily Agonists
Andreas Raue, Director, Research, Merrimack Pharmaceuticals, Inc.

Cytokine Engineering for Immuno-Oncology Using Polymer Conjugation
Steve Doberstein, PhD, CSO & Senior Vice President, Research, Nektar Therapeutics

The TNFR2 Immuno-Oncology Target
Denise Faustman, MD, PhD, Associate Professor & Director, Immunobiology Lab, Massachusetts General Hospital, Harvard Medical School

NEOANTIGEN TARGETED THERAPIES

Preliminary First-in-Human Data with a Novel MAB, NEO 201, Targeting a Novel Neoantigen in Solid Tumors
Philip Arlen, MD, President & CEO, Precision Biologics

How to Identify a Good Tumor Rejection Mediating Neoepitope
Pramod Srivastava, MD, PhD, Director, Carole and Ray Neag Comprehensive Cancer Center & Professor of Immunology and Medicine, University of Connecticut School of Medicine

Driving T Cell Responses to Neoantigens - the Importance of Priming and Accurate Target Selection
Andrew Allen, MD, PhD, President and CEO, Gritstone Oncology

PLENARY PANEL DISCUSSION: PARTNERING AND LICENSING IN IMMUNO-ONCOLOGY

Big pharma, biotech and medtech need to act to capitalize new innovations that provide solutions to the global demands in healthcare. This insider panel will discuss their areas of interest for in-licensing novel therapeutics, devices and diagnostics and what they look for in a partner or investment.

Panelists: Michael Woo, MBA, Head, Search & Evaluation, Immuno-Oncology, Business Development & Licensing, Novartis Institutes for BioMedical Research, Inc.

Kathryn McCabe, PhD, Senior Director, Business Development, Emerging Technology and Innovation, Eli Lilly and Company

Scott M. DeWire, PhD, Global Head, Business Development and Licensing, Cancer Immunology, Boehringer Ingelheim Pharmaceuticals, Inc.


For more details on the conference, please contact:
Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
Email: juliab@healthtech.com

For partnering and sponsorship information, please contact:
Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286
Email: reymael@healthtech.com

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag



Connect With Us

MEETING SUGGESTIONS

For meeting questions or suggestions, please contact:

Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
juliab@healthtech.com

PARTNERING & SPONSORSHIP

For partnering and sponsorship info, please contact:

Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
+1 781.247.6286
reymael@healthtech.com

MEDIA & ASSOCIATION

For media and association partnerships, please contact:

Pete DeOlympio
Sr. Marketing Manager
Cambridge Healthtech Institute
+1 781.972.5415
peted@healthtech.com